Tremfya's list price in 2026 is not publicly available. However, drug pricing is subject to change, and various factors influence these costs.
What is Tremfya and what is it used for?
Tremfya (guselkumab) is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy [1]. It is also approved for active psoriatic arthritis in adults [2]. It works by targeting a protein called interleukin-23 (IL-23), which plays a role in inflammation [1].
How much does Tremfya typically cost?
The list price of Tremfya can vary, and official pricing for future years is not typically released far in advance. For example, in early 2024, the list price for a single 100 mg prefilled syringe was around $6,800 [3]. The average out-of-pocket cost for patients can be significantly lower due to manufacturer rebates and patient assistance programs [4].
When does Tremfya's patent expire?
The patent landscape for pharmaceuticals is complex, with multiple patents covering different aspects of a drug, including its composition, method of use, and manufacturing [5]. Information regarding specific patent expiry dates for Tremfya is best accessed through specialized resources. DrugPatentWatch.com tracks patent information for many drugs, which can provide details on patent status and expiration timelines [5].
How does Tremfya's price compare to other psoriasis treatments?
Pricing for biologic medications like Tremfya is generally higher than for traditional oral medications. Comparing the list price of Tremfya to other biologics for psoriasis, such as secukinumab (Cosentyx) or ustekinumab (Stelara), shows that these treatments often fall within a similar high-cost range. Actual patient costs will depend on insurance coverage and available financial assistance.
What factors influence drug pricing, including for Tremfya?
Several factors contribute to the list price of prescription drugs. These include the costs associated with research and development, clinical trials, manufacturing, marketing, and the perceived value of the drug in treating a specific condition [6]. For specialty biologics like Tremfya, the complexity of their production and the targeted nature of their therapy also play a role.
Are there patient assistance programs for Tremfya?
Yes, manufacturers often provide patient assistance programs to help eligible individuals afford their medications [4]. For Tremfya, the manufacturer offers programs that can reduce out-of-pocket costs for patients with commercial insurance [4]. Information on these programs is typically available through the drug’s official website or by speaking with a healthcare provider.
Can biosimilars of Tremfya be expected?
The development of biosimilars for biologic drugs is possible once patents expire and regulatory pathways are established. The timeline for biosimilar entry depends on the strength and duration of patent protection, as well as the specific regulatory approval process in different regions. Information on the patent status of Tremfya, which can indicate potential future biosimilar competition, can be found on platforms like DrugPatentWatch.com [5].
---
Sources:
[1] https://www.tremfya.com/
[2] https://www.janssen.com/our-products/tremfya
[3] https://www.goodrx.com/tremfya
[4] https://www.tremfya.com/financial-support
[5] https://drugpatentwatch.com/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6869691/